A computational systems biology software platform for multiscale modeling and simulation: Integrating whole-body physiology, disease biology, and molecular reaction networks

Frontiers in Physiology

Volumn FEB, Issue , 2011, Pages

  Eissing, Thomas ^a   Kuepfer, Lars ^a   Becker, Corina ^a   Block, Michael ^a   Coboeken, Katrin ^a   Gaub, Thomas ^a   Goerlitz, Linus ^a   Jaeger, Juergen ^a   Loosen, Roland ^a   Ludewig, Bernd ^a   Meyer, Michaela ^a   Niederalt, Christoph ^a   Sevestre, Michael ^a   Siegmund, Hans Ulrich ^a   Solodenko, Juri ^a   Thelen, Kirstin ^a   Telle, Ulrich ^a   Weiss, Wolfgang ^a   Wendl, Thomas ^a   Willmann, Stefan ^a   Lippert, Joerg ^a   more..

^a BAYER AG   (Germany)

Author keywords

Modeling; Multiscale; Oncology; Pbpk; Signal transduction; Simulation; Software; Systems biology

Indexed keywords

EID: 80054718671     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2011.00004     Document Type: Article

References (60)

1. Araujo, R. P., and McElwain, D. L. (2004). A history of the study of solid tumour growth: the contribution of math-ematical modelling. Bull. Math. Biol. 66, 1039-1091.
2. Berezhkovskiy, L. M. (2004). Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J. Pharm. Sci. 93, 1628-1640.
3. Block, M., Scholl, E., and Drasdo, D. (2007). Classifying the expansion kinetics and critical surface dynamics of growing cell populations. Phys. Rev. Lett. 99, 248101.
4. Briest, S., and Stearns, V. (2009). Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin. Adv. Hematol. Oncol. 7, 185-192.
5. Brightman, F. A., and Fell, D. A. (2000). Differential feedback regulation of the MAPK cascade underlies the quanti-tative differences in EGF and NGF signalling in PC12 cells. FEBS Lett. 482, 169-174.
6. Bru, A., Albertos, S., Luis Subiza, J., Garcia-Asenjo, J. L., and Bru, I. (2003). The universal dynamics of tumor growth. Biophys. J. 85, 2948-2961.
7. Butcher, E. C., Berg, E. L., and Kunkel, E. J. (2004). Systems biology in drug dis-covery. Nat. Biotechnol. 22, 1253-1259.
8. Chong, L., and Ray, L. B. (2002). Whole-istic biology. Science 296, 1661. Cohen, S. D., and Hindmarsh, A. C. (1996). CVODE, a stiff/nonstiff ODE solver in C. Comput. Phys. 10, 138-143.
9. Cohen-Saidon, C., Cohen, A. A., Sigal, A., Liron, Y., and Alon, U. (2009). Dynamics and variability of ERK2 response to EGF in individual living cells. Mol. Cell 36, 885-893.
10. Deisboeck, T. S. (2009). Personalizing medicine: a systems biology perspec-tive. Mol. Syst. Biol. 5, 249.
11. Edginton, A. N., Schmitt, W., Voith, B., and Willmann, S. (2006a). A mechanistic approach for the scaling of clearance in children. Clin. Pharmacokinet. 45, 683-704.
12. Edginton, A. N., Schmitt, W., and Willmann, S. (2006b). Application ofphysiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions. Adv. Ther. 23, 143-158.
13. Edginton, A. N., Schmitt, W., and Willmann, S. (2006c). Development and evaluation of a generic physiologi-cally based pharmacokinetic model for children. Clin. Pharmacokinet. 45, 1013-1034.
14. Edginton, A. N., Theil, F. P., Schmitt, W., and Willmann, S. (2008). Whole body physiologically-based pharma-cokinetic models: their use in clinical drug development. Expert Opin. Drug Metab. Toxicol. 4, 1143-1152.
15. Edginton, A. N., and Willmann, S. (2008). Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis. Clin. Pharmacokinet. 47, 743-752.
16. Elowitz, M. B., Levine, A. J., Siggia, E. D., and Swain, P. S. (2002). Stochastic gene expression in a single cell. Science 297, 1183-1186.
17. Espie, P., Tytgat, D., Sargentini-Maier, M. L., Poggesi, I., and Watelet, J. B. (2009). Physiologically based phar-macokinetics (PBPK). Drug Metab. Rev. 41, 391-407.
18. Greenspan, H. P. (1976). On the growth and stability of cell cultures and solid tumors. J. Theor. Biol. 56, 229-242.
19. Heinrich, R., and Rapoport, T. A. (1974). A linear steady-state treatment of enzymatic chains. General properties, control and effector strength. Eur. J. Biochem. 42, 89-95.
20. Heinrich, R., and Schuster, S. (1996). The Regulation of Cellular Systems. New York: Chapman and Hall.
21. Hester, R. L., Iliescu, R., Summers, R. L., and Coleman, T. G. (2010). Systems biology and integrative physiologi-cal modeling. J. Physiol. doi: 10.1113/ jphysiol.2010.201558. [Epub ahead of print].
22. Hucka, M., Finney, A., Sauro, H. M., Bolouri, H., Doyle, J. C., Kitano, H., Arkin, A. P., Bornstein, B. J., Bray, D., Cornish-Bowden, A., Cuellar, A. A., Dronov, S., Gilles, E. D., Ginkel, M.,Gor, V., Goryanin, I. I., Hedley, W. J., Hodgman, T. C., Hofmeyr, J. H., Hunter, P. J., Juty, N. S., Kasberger, J. L., Kremling, A., Kummer, U., Le Novère, N., Loew, L. M., Lucio, D., Mendes, P., Minch, E., Mjolsness, E. D., Nakayama, Y., Nelson, M. R., Nielsen, P. F., Sakurada, T., Schaff, J. C., Shapiro, B. E., Shimizu, T. S., Spence, H. D., Stelling, J., Takahashi, K., Tomita, M., Wagner, J., and Wang, J. (2003). The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 19, 524-531.
23. Kacser, H., and Burns, J. A. (1973). The control of flux. Symp. Soc. Exp. Biol. 27, 65-104.
24. Kalow, W. (2006). Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medi-cine. Pharmacogenomics J. 6, 162-165.
25. Krishan, K., and Johanson, G. (2005). Physiologically-based pharmacoki-netic and toxicokinetic models in cancer risk assessment. J. Environ. Sci. Health 23, 31-53.
26. Kuepfer, L. (2010). Towards whole-body systems physiology. Mol. Syst. Biol. 6, 409.
27. Loizou, G., Spendiff, M., Barton, H. A., Bessems, J., Bois, F. Y., d'Yvoire, M. B., Buist, H., Clewell, H. J. III, Meek, B., Gundert-Remy, U., Goerlitz, G., and Schmitt, W. (2008). Development of good modelling practice for physi-ologically based pharmacokinetic models for use in risk assessment: the first steps. Regul. Toxicol. Pharmacol. 50, 400-411.
28. Marusic, M., Bajzer, Z., Vuk-Pavlovic, S., and Freyer, J. P. (1994). Tumor growth in vivo and as multicellular spheroids compared by mathematical models. Bull. Math. Biol. 56, 617-631.
29. Nestorov, I. (2007). Whole-body physi-ologically based pharmacokinetic models. Expert Opin. Drug Metab. Toxicol. 3, 235-249.
30. Poulin, P., Schoenlein, K., and Theil, F. P. (2001). Prediction of adipose tissue: plasma partition coefficients for struc-turally unrelated drugs. J. Pharm. Sci. 90, 436-447.
31. Poulin, P., and Theil, F. P. (2002a). Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J. Pharm. Sci. 91, 129-156.
32. Poulin, P., and Theil, F. P. (2002b). Prediction of pharmacokinetics prior to in vivo studies. II. Generic physi-ologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. 91, 1358-1370.
33. Radszuweit, M., Block, M., Hengstler, J. G., Scholl, E., and Drasdo, D. (2009).Comparing the growth kinetics of cell populations in two and three dimen-sions. Phys. Rev. E. Stat. Nonlin. Soft Matter Phys. 79(Pt 1),051907.
34. Rae, J. M., Sikora, M. J., Henry, N. L., Li, L., Kim, S., Oesterreich, S., Skaar, T. C., Nguyen, A. T., Desta, Z., Storniolo, A. M., Flockhart, D. A., Hayes, D. F., and Stearns, V. (2009). Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast can-cer patients. Pharmacogenomics J. 9, 258-264.
35. Rao, C. V., Wolf, D. M., and Arkin, A. P. (2002). Control, exploitation and tol-erance of intracellular noise. Nature 420, 231-237.
36. Rodgers, T., Leahy, D., and Rowland, M. (2005a). Physiologically based phar-macokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 94, 1259-1276.
37. Rodgers, T., Leahy, D., and Rowland, M. (2005b). Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. J. Pharm. Sci. 94, 1237-1248.
38. Rodgers, T., and Rowland, M. (2006). Physiologically based pharmacoki-netic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 95, 1238-1257.
39. Rodgers, T., and Rowland, M. (2007). Mechanistic approaches to volume of distribution predictions: under-standing the processes. Pharm. Res. 24, 918-933.
40. Sauro, H. M. (1993). SCAMP: a general-purpose simulator and metabolic con-trol analysis program. Comput. Appl. Biosci. 9, 441-450.
41. Schmitt, W. (2008). General approach for the calculation of tissue to plasma partition coefficients. Toxicol. In Vitro 22, 457-467.
42. Shampine, L. F. (2005). Solving ODEs and DDEs with residual control. Appl. Num. Math. 52, 113-127.
43. Sigal, A., Milo, R., Cohen, A., Geva-Zatorsky, N., Klein, Y., Liron, Y., Rosenfeld, N., Danon, T., Perzov, N., and Alon, U. (2006). Variability and memory of protein levels in human cells. Nature 444, 643-646.
44. Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G., and Fuselli, S. (2007). CYP2D6 worldwide genetic varia-tion shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17, 93-101.
45. Sobol', I. M. (2001). Global sensitivity indices for nonlinear mathemati-cal models and their Monte Carloestimates. Math. Comp. Simul. 55, 271-280.
46. Spencer, S. L., Gaudet, S., Albeck, J. G., Burke, J. M., and Sorger, P. K. (2009). Non-genetic origins of cell-to-cell variability in TRAIL-induced apop-tosis. Nature 459, 428-432.
47. Stites, E. C., Trampont, P. C., Ma, Z., and Ravichandran, K. S. (2007). Network analysis of oncogenic Ras activation in cancer. Science 318, 463-467.
48. Tomalik-Scharte, D., Lazar, A., Fuhr, U., and Kirchheiner, J. (2008). The clini-cal role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J. 8, 4-15.
49. Tornoe, C. W., Agerso, H., Jonsson, E. N., Madsen, H., and Nielsen, H. A. (2004). Non-linear mixed-effects pharmacok-inetic/pharmacodynamic modelling in NLME using differential equations. Comput. Methods Programs Biomed. 76, 31-40.
50. Vossen, M., Sevestre, M., Niederalt, C., Jang, I. J., Willmann, S., and Edginton, A. N. (2007). Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body phys-iologically-based pharmacokinetic (WB-PBPK) models. Theor. Biol. Med. Model. 4, 13.
51. Willmann, S., Edginton, A. N., and Dressman, J. B. (2007a). Development and validation of a physiology-based model for the prediction of oral absorption in monkeys. Pharm. Res. 24, 1275-1282.
52. Willmann, S., Hohn, K., Edginton, A., Sevestre, M., Solodenko, J., Weiss, W., Lippert, J., and Schmitt, W. (2007b). Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 34, 401-431.
53. Willmann, S., Edginton, A. N., Kleine-Besten, M., Jantratid, E., Thelen, K., and Dressman, J. B. (2009a). Whole-body physiologically based pharma-cokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. J. Pharm. Pharmacol. 61, 891-899.
54. Willmann, S., Edginton, A. N., Coboeken, K., Ahr, G., and Lippert, J. (2009b). Risk of codeine treatment dur-ing breastfeeding - a quantitative mechanistic modeling study. Clin. Pharmacol. Ther. 86, 634-643.
55. Willmann, S., Lippert, J., and Schmitt, W. (2005). From physicochemistry to absorption and distribution: predic-tive mechanistic modelling and com-putational tools. Expert Opin. Drug Metab. Toxicol. 1, 159-168.
56. ®: a physiologically based pharmacokinetic 'whole-body' model. Biosilico 1, 121-124.
57. Willmann, S., Schmitt, W., Keldenich, J., and Dressman, J. B. (2003b). A physiologic model for simulat-ing gastrointestinal flow and drug absorption in rats. Pharm. Res. 20, 1766-1771.
58. Willmann, S., Schmitt, W., Keldenich, J., Lippert, J., and Dressman, J. B. (2004). A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 47, 4022-4031.
59. Zanger, U. M., Fischer, J., Raimundo, S., Stuven, T., Evert, B. O., Schwab, M., and Eichelbaum, M. (2001). Comprehensive analysis of the genetic factors determining expres-sion and function of hepatic CYP2D6. Pharmacogenetics 11, 573-585.
60. Zi, Z., Zheng, Y., Rundell, A. E., and Klipp, E. (2008). SBML-SAT: a sys-tems biology markup language (SBML) based sensitivity analysis tool. BMC Bioinformatics 9, 342. doi: 10.1186/1471-2105-9-342